Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
about
Continued lamivudine for adults with lamivudine-resistant chronic hepatitis B virus infectionAntiviral treatments for lamivudine-resistant chronic hepatitis B adult patientsCurrent and future directions for treating hepatitis B virus infectionRoles of hepatocyte nuclear factors in hepatitis B virus infectionCurrent and future antiviral drug therapies of hepatitis B chronic infectionThe hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymesSubgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the West Bank, palestineDifferential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virusSubstitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug ResistanceNovel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.Application of hepatitis B virus replication mouse modelHepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activityA cutting-edge view on the current state of antiviral drug development.Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis BUracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA.Unveiling the roles of HBV polymerase for new antiviral strategiesA comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B.The hepatitis B virus ribonuclease H as a drug targetPrecore/basal core promoter mutants quantification throughout phases of hepatitis B virus infection by SimpleprobeTransposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.Antiviral therapies: focus on hepatitis B reverse transcriptaseInhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compoundsDrug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.Antiviral resistance and hepatitis B therapy.Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B.Entecavir for the long-term treatment of chronic hepatitis B.Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B.New perspective on the natural course of chronic HBV infection.Molecular diagnosis and treatment of drug-resistant hepatitis B virus.Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults.HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data MiningNew amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.Hepatitis B virus (HBV) variants fluctuate in paired plasma and peripheral blood mononuclear cells among patient cohorts during different chronic hepatitis B (CHB) disease phases.Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report.Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B.Synthesis and anti-HBV activity of novel 3'-N-phenylsulfonyl docetaxel analogs.An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription
P2860
Q24185958-993A2231-D7EE-4430-B2E2-B87B14E91D76Q24241469-8A5FD37E-9DA2-4132-A2FB-50F7B6313E1EQ26851240-CB3B0905-906A-403C-8FC1-659363A2557DQ28069574-821DC209-16B9-4DE1-A396-FE8EADBD6F50Q28084820-A82EABAE-D065-4557-893C-0A5A17073459Q28485228-E1BA01FE-A39A-470C-BCFB-15868A17ACFBQ28542694-64BEF8D3-D382-45B6-B2D3-2BA1D789B686Q28542705-29890EF5-D3B4-4F50-884E-B9FA9BD1A590Q28547647-70159F13-145F-4D69-93AA-F52CB54AF163Q33553814-F548932B-450E-4853-BC05-1D6F64BD82B9Q33812160-0031F67D-3E23-45ED-A5CF-9F0CBF5B7622Q33911464-4485B9E4-F83A-44B5-AE5D-CA5C78317469Q34036018-D2437905-2443-43E0-BBEB-F23DF39BA0F4Q34045308-29331801-0B4E-4C1A-A6D0-BE318E9B8746Q34591879-3B4FC3D2-60AA-4680-9C08-FB750189DD4FQ34733579-F161DE94-309A-477F-AE4F-A6B3B64F07C7Q35441503-251042FC-36E8-4375-849A-FD512A2CB20DQ35507167-AB299C95-FBDC-4C2B-BF46-7EDD6873C27FQ35582561-D1F0CF01-6624-4921-969A-A0BC06167141Q35692307-72C84923-68CC-4BEC-AB20-17F44D9D9DAEQ36269684-22DB6D65-0ABA-4593-8509-AB8C3F759F4BQ36467514-AEEB6136-670D-4CBB-B967-E071B7DD349DQ36483826-A37B6A89-0277-4601-AE9C-1C980E09EE5DQ36765571-4D664734-47C8-4C59-85ED-E74DA317F703Q37255008-C55D7FB6-4A27-4DB0-9067-4120D4DF1DBAQ37488838-15DBDBD3-DD8C-4F1F-A8BF-0913D3667BECQ37626058-EADA474A-33DF-4CAF-9E36-E8F4F8A3DE3AQ37678183-1885C077-EF79-4396-A0C7-F816E6C55F7AQ38100847-82EE2FF1-CCE0-4E39-BD4C-686ACE7CD43AQ38215650-40313FE2-B014-4BB5-A9BA-7DE6B3CD3381Q38219020-02E92B35-23C5-43AC-85B4-7AD727A68A96Q38424625-79B29512-D204-429A-8A35-F2FADD999D5FQ38648688-EAF5ED90-3292-42B1-980E-7632372F39ABQ38657888-D66C43DD-E631-4479-B607-3B618B13805DQ41454895-8135DADC-7148-4D0F-87A8-F94320343A90Q41746406-C0B1449C-4C63-439F-8C63-974EB5A6D386Q41965007-03C8731B-D72C-47A6-AB71-DAF3B153F51FQ42174830-89086427-2888-4DBF-83AA-257ACFC1FAD5Q42274493-3A02D408-CBB6-45CB-9698-EF7B5286D26DQ42545491-3295DEC5-4AB0-41AE-A536-1A9AABD8C2D3
P2860
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
@ast
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
@en
type
label
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
@ast
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
@en
prefLabel
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
@ast
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
@en
P1433
P1476
Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.
@en
P2093
Marc Ghany
T Jake Liang
P304
P356
10.1053/J.GASTRO.2007.02.039
P407
P577
2007-04-01T00:00:00Z